Garadacimab

How it works

It inhibits activated factor XII (factor XIIa), reducing activation of the contact (kallikrein-kinin) system and thereby decreasing bradykinin-mediated angioedema attacks.

Prescribing in practice

• It is intended for routine prevention of attacks, not for treating an acute attack, so patients must retain access to a recognised acute hereditary angioedema treatment.
• Use under specialist supervision for confirmed hereditary angioedema and counsel on injection technique where self-administration is used.
• Consider bleeding risk and refer to the SPC before use in patients on anticoagulants or with bleeding disorders.

Monitoring

Monitor attack frequency and severity and overall treatment response under specialist follow-up.

Counselling the patient

• Explain that this medicine is taken regularly to prevent angioedema attacks, not to treat one that has started.
• Stress that on-demand rescue treatment must always be available.
• Advise reporting any unusual bleeding or bruising.

Evidence & guidelines

Garadacimab is a factor XIIa inhibitor developed for long-term prophylaxis of hereditary angioedema attacks.